In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 1921-1926

  Ji, Baohong ^a   Lefrançois, Sébastien ^a   Robert, Jerome ^a   Chauffour, Aurélie ^a   Truffot, Chantal ^a   Jarlier, Vincent ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; LINEZOLID; MOXIFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BURULI ULCER; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; INFECTION PREVENTION; MONOTHERAPY; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOT; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM ULCERANS; NITROIMIDAZOLES; OXAZOLIDINONES; QUINOLINES; RIFAMPIN; STREPTOMYCIN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33744470095     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00052-06     Document Type: Article

References (27)

1. Alcala, L., M. J. Ruiz-Serrano, C. Pérez-Fernandez Turégano, D. G. de Viedma, M. Diaz-Infantes, M. Marin-Arriaza, and E. Bouza. 2003. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother. 47:416-417.
2. Andries, K., P. Verhasselt, J. Guillemont, H. W. H. Göhlmann, J. Neefs, H. Winkler, J. V. Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227.
3. Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45:3109-3112.
4. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. R. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, A. A. Vernon, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
5. Brown-Elliott, B. A., C. J. Crist, L. B. Mann, R. W. Wilson, and R. J. Wallace, Jr. 2003. In vitro activity of linezolid against slowly growing non-tuberculous mycobacteria. Antimicrob. Agents Chemother. 47:1736-1738.
6. Chauty, A. 2005. Treatment of Buruli ulcer with the combination rifampicin and streptomycin in Benin. Presented at the 8th Annual World Health Organization Advisory Group Meeting on Buruli ulcer, http://www.who.int /gtb-buruli/publications.
7. Consigny, S., A. Bentoucha, P. Bonnafous, J. Grosset, and B. Ji. 2000. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob. Agents Chemother. 44:2919-2921.
8. Cynamon, M. H., S. P. Klemens, C. A. Sharpe, and S. Chase. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43:1189-1191.
9. Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset, 2000. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 44:2367-2372.
10. Dega, H., A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset. 2002. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 46:3193-3196.
11. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186.
12. Food and Drug Administration. 2004. www.fda.gov/cder/foi/appletter/2004 /19537s049,19857s031,19847s027,20780s013ltr.pdf-03-28-2004.
13. Grady, R. 2003. Safety profile of quinolone antibiotics in the pediatric population. Pediatr. Infect. Dis. J. 22:1128-1132.
14. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069.
15. Ji, B., A. Chauffeur, K. Andries, and V. Jarlier. 2006. Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice. Antimicrob. Agents Chemother. 50:1558-1560.
16. Jindani, A., C. J. Doré, and D. A. Mitchison. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167:1348-1354.
17. Johnson, P. D. R., T. Stinear, P. L. C. Small, G. Plushke, R. W. Merritt, F. Portaels, K. Huygen, J. A. Hayman, and K. Asiedu. 2005. Buruli ulcer (M. ulcerons infection): new insights, new hope for disease control. PLOS Med. 2:282-286.
18. Lenaerts, A. J., V. Gruppe, K. S. Marietta, C. M. Johnson, D. K. Driscoll, N. M. Tompkins, J. D. Rose, R. C. Reynolds, and I. M. Orme. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301.
19. Marsollier, L., G. Prévot, N. Honoré, P. Legras, A. Manceau, C. Payan, H. Kouakou, and B. Carbonnelle. 2003. Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin. Int. J. Antimicrob. Agents 22:562-566.
20. Owen, R. C., and P. G. Ambrose, 2005. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis. 41.-S144-S157.
21. Portaels, F., H. Traore, K. de Ridder, and W. M. Meyers. 1998. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42:2070-2073.
22. Stover, C. K., P. Warrener, D. R. VanDevanter, D. R. Sherman, T. M. Arain, M. H. Langhorne, S. W. Andersen, J. A. Towell, Y. Yuan, D. N. McMurray, B. N. Kreiswirth, C. E. Barry, and W. R. Baker. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-966.
23. Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49:2289-2293.
24. van der Werf, T. S., W. T. A. van der Graaf, J. W. Tappero, and K. Asiedu. 1999. Mycobacterium ulcerans infection. Lancet 354:1013-1018.
25. van der Werf, T. S., T. Stinear, Y. Stienstra, W. T. A. van der Graaf, and P. L. Small. 2003. Mycolactones and Mycobacterium ulcerans disease. Lancet 362:1062-1064.
26. Wallace, R. J., Jr., B. A. Brown-Elliott, S. C. Ward, C. J. Crist, L. B. Mann, and R. W. Wilson. 2001. Activities of linezolid against rapidly growing mycobacteria. Antimicrob. Agents Chemother. 45:764-767.
27. World Health Organization. 2004. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). WHO/CDS/CPE/GBUI/2004.10.